| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
(Former Name or Former Address, if Changed Since Last Report) |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
DALLAS, TX, August 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial results and... |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2026, Instil Bio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail i... |
| 15 May 2026 |
8-K: Results of Operations and Financial Condition
DALLAS, TX, May 15, 2026 (GLOBE NEWSWIRE) - Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its first quarter 2026 financial results and prov... |
| 03 Apr 2026 |
8-K: Changes in Registrant's Certifying Accountant
We have read Item 4.01 of Instil Bio, Inc.'s Form 8-K dated April 3, 2026, and have the following comments: |
| 27 Mar 2026 |
8-K: Results of Operations and Financial Condition
Company evaluating potential acquisitions and in-licensing opportunities to drive next phase of strategic development |
| 06 Jan 2026 |
8-K: Termination of a Material Definitive Agreement
On January 5, 2026, Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil Bio, Inc., and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (“ImmuneOnco”) entered into an agreement terminating, effective January 5, 2026, the License ... |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
First patient dosed in Phase 1 clinical trial evaluating AXN-2510/IMM2510 (“ ‘2510 ”) monotherapy in adult patients with advanced solid tumors |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition
With the clearance of the U.S. IND, initiation of the U.S. clinical trial of AXN-2510/IMM2510 (“’2510”) anticipated before the end of 2025 |
| 31 Jul 2025 |
8-K: Other Events
On July 31, 2025, Instil Bio, Inc. reported that ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (“ImmuneOnco”) announced preliminary safety and efficacy data from the ongoing Phase 2 open-label, multicenter study of IMM2510/AXN-2510 (“‘25... |
| 28 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On May 28, 2025, Instil Bio, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail in... |
| 27 May 2025 |
8-K: Regulation FD Disclosure; Other Events
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Res... |
| 22 May 2025 |
8-K: Regulation FD Disclosure
Instil Bio Corporate Presentation May 2025 Nasdaq: TIL | www.instilbio.com EX-99.1 |
| 13 May 2025 |
8-K: Results of Operations and Financial Condition
Enrollment of 1L NSCLC patients in China trial of AXN-2510/IMM2510 in combination with chemotherapy is ongoing with initial clinical data by ImmuneOnco expected in 2H 2025 |
| 31 Mar 2025 |
8-K: Entry into a Material Definitive Agreement
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM March 28, 2025 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Instil Bio, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditio... |
| 04 Mar 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Clinical data for AXN-2510/IMM2510 monotherapy in relapsed/refractory NSCLC in China by ImmuneOnco, as well as additional safety data in other solid tumors, anticipated in 1H 2025 |
| 14 Jan 2025 |
8-K: Other Events
ImmuneOnco announced dosing of first patient in its recently initiated Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy in patients with advanced NSCLC in China |
| 23 Dec 2024 |
8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more
On December 20, 2024 (the “Closing Date”), Complex Therapeutics LLC (“Borrower”), a wholly-owned subsidiary of Instil Bio, Inc. (the “Company”), entered into a Term Loan Agreement (the “2024 Loan Agreement”) and related loan documents wi... |
| 13 Nov 2024 |
8-K: Results of Operations and Financial Condition
Licensed SYN-2510, a potential best-in-class PD-L1xVEGF bispecific antibody, for global ex-China development and commercialization |
| 16 Sep 2024 |
8-K: Regulation FD Disclosure; Other Events
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer |
Loading...